Grifols SA earnings date
Grifols SA (G0FB) Q3 2026 Earnings Report
DE:G0FB Q3 2026 EPS Results
- Actual EPS
- EUR 0.25
- Consensus EPS
- EUR 0.29
- Beat/Miss
- Missed by -EUR 0.04
- One Year Ago EPS
- EUR 0.20
DE:G0FB Q3 2026 Revenue Results
- Actual Revenue
- EUR 2.10B
- Expected Revenue
- EUR 1.98B
- Beat/Miss
- Beat by +EUR 121.27M
- YoY Revenue Growth
- +7.67%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/02/2026
- Time
- During Market Hours
- Conference Call
- Monday, November 2, 2026
Grifols SA's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was clearly positive overall. Strong Biopharma and IG growth, expanding EBITDA margins, higher profit and free cash flow, organic deleveraging, stronger liquidity, the Egypt plasma ramp-up and continued strategic progress significantly outweighed the challenges. The main negatives were the sharp decline and slower-than-expected recovery in China albumin, the reported Diagnostics decline from the dissolved joint business, foreign-exchange headwinds, a tougher Q4 comparison and ongoing regulatory scrutiny.
Management reiterated 2026 guidance for an adjusted EBITDA margin of 25%, free cash flow before M&A guidance with an upper part of EUR 570 million, and Alpha-1 and Specialty Proteins growth of 5% mid-single-digit growth; Q4 '26 is expected to show modest growth versus Q4 '25, with Q4 '26 better, but only modestly so, while full-year gross margin remains benchmarked at 38%. Egypt is on track to collect approximately 1 million liters in 2026, expand from 18 collection centers today to 20 by the first quarter of 2027, and develop an additional 20 centers in the coming years to support 3 million liters of annual plasma collection; SPARTA top line results are expected in late Q4 '26 with a market presentation in Q1 '27, depending on timing, and management does not expect an update on the U.S. IPO until 2027.
- Strong Third-Quarter Revenue and EBITDA GrowthQ3 2026 group revenue grew 8.4% at constant currency to EUR 2.04 billion, while adjusted EBITDA reached EUR 538 million, up 9.8% year over year. Adjusted EBITDA margin expanded 60 basis points to 26.4%.
- Nine-Month Performance Remains on TrackNine-month revenue reached EUR 5.614 billion, up 4.6% at constant currency, and adjusted EBITDA reached EUR 1.392 billion, up 5%. The nine-month adjusted EBITDA margin was 24.8%, keeping the company on track for its full-year adjusted EBITDA margin guidance of 25%.
- Improved Profitability and Cash GenerationGroup profit increased 28.4% year over year to EUR 390 million through the first nine months. Free cash flow before M&A reached EUR 298 million, up 59%, or EUR 110 million, year over year.
- Organic Deleveraging and Stronger LiquidityTotal net leverage declined to 3.98x from 5.5x in June 2024, while secured net leverage stood at 2.5x. Liquidity was EUR 2.14 billion, more than three times the level in September 2024, and the company has no significant maturities until the fourth quarter of 2028.
- Interim Dividend ApprovedThe Board approved a 2026 interim dividend of EUR 0.15 per share, payable in early December 2026, based on the company's year-to-date performance and financial position.
- Biopharma Led Group GrowthBiopharma revenue grew 10.3% in Q3 at constant currency and was the primary driver of the group's 8.4% revenue growth. Growth was supported by industry volume expansion, commercial execution, favorable product mix and continued operating discipline.
- Immunoglobulin Growth Remained StrongIG revenue grew 11.3% in Q3 and 12.3% year to date at constant currency. Subcutaneous IG revenue increased 40.3% in Q3 and 25.6% year to date, supported by demand for XEMBIFY and growth across both IV and subcutaneous therapies.
- Diversified IG Demand and Clinical OpportunitiesThe company reported sustained growth across primary immunodeficiency, secondary immunodeficiency and CIDP. Secondary immunodeficiencies continued to deliver double-digit growth, while CIDP delivered mid- to high single-digit growth through the first six months of 2026. The SIGMA, EXCEL and EXPERT studies are intended to support additional opportunities across IV and subcutaneous therapies.
- Alpha-1 and Specialty Proteins Delivered Strong GrowthAlpha-1 and Specialty Proteins revenue increased 18.2% in Q3, supported by a significant contribution from Rabies. Full-year growth guidance for the portfolio remains mid-single-digit, or 5%, and management said it remains comfortable with that guidance.
- Diagnostics Underlying Business GrewAlthough reported Diagnostics revenue declined because of the dissolved QuidelOrtho joint business, the underlying business grew 2.3% through nine months. Blood typing solutions grew at high single-digit or mid- to high single-digit rates, while NAT grew by a couple of percentage points.
- Diagnostics Repositioning and Product DevelopmentFollowing the Q2 launch of Evanzys IH, the company continued developing ISARD, its immunoassay platform, and MUNDAKA, its molecular NAT platform. Management said the resolution of the QuidelOrtho joint business better positions Diagnostics to pursue innovation-led opportunities in adjacent markets.
- Egypt Plasma Collection Scaled RapidlyMonthly plasma collection volumes in Egypt nearly doubled since the beginning of 2026, putting the company on track to collect approximately 1 million liters in 2026. The network has 18 collection centers and is expected to expand to 20 by the first quarter of 2027, with an additional 20 centers planned in the coming years to support 3 million liters of annual collection.
- Egypt Integrated Into Global Plasma SourcingEuropean Medical Authority approval enabled the progressive integration of Egyptian plasma into Grifols' global sourcing network for international markets. Management said Egypt has structurally attractive plasma collection costs and higher protein yields, with expected contributions increasing in 2027 and further in 2028 and 2029.
- Egypt Achieved Local Self-Sufficiency MilestoneThe company stated that Egypt achieved full self-sufficiency in Factor VIII, albumin and Ig during the prior year. Grifols continues developing fractionation, purification, testing and logistics infrastructure to create an integrated end-to-end plasma platform.
- Progress on Alpha-1 Clinical, Convenience and Diagnostic InitiativesThe SPARTA study is expected to produce top-line results in late Q4 2026, with a presentation planned for Q1 2027. The study evaluates standard-dose and double-dose PROLASTIN-C versus placebo over three years, measuring change from baseline in whole-lung PD15 on CT densitometry. The Alpha-1 subcutaneous 15% program is in Phase III, and the company is also working with AlphaDetect to improve screening and diagnosis.
- New Specialty Protein Product LaunchedThe U.S. team launched FESILTY, a fibrinogen concentrate for patients with congenital fibrinogen deficiency, in June 2026.
- Gross Margin and Cost Performance ImprovedReported gross margin reached 39.6% in Q3 and 38% through nine months. The improvement was driven by Biopharma volume growth, favorable product mix, optimization of plasma sourcing and collection costs, and initial contributions from Egypt, despite stated headwinds from China albumin, donor center restructuring, Yimmugo and Diagnostics.
- Cash Conversion and Balance-Sheet Flexibility ImprovedFree cash flow conversion exceeded 20% of EBITDA through nine months, although management noted that the figure benefited from phasing-related gains. The company redeemed EUR 500 million of its most expensive debt earlier in the year, and most debt is callable or prepayable without significant penalties.
- ERP Upgrade CompletedGrifols successfully completed its upgrade to SAP S/4HANA, which management described as an important milestone strengthening the IT infrastructure supporting the business.
- Canada Plasma Collection Began Phased ResumptionAfter voluntarily pausing plasma collection at all 17 Canadian donation centers in mid-August, Grifols began a phased resumption in coordination with Health Canada and Canadian Blood Services. Commercial operations continued uninterrupted using plasma sourced from the U.S.
- Ongoing Strategic Initiatives and Potential U.S. Biopharma IPO ReviewThe company continues assessing a potential IPO of its U.S. Biopharma business. Management said the Board's focus is on unlocking value and that updates will be provided when appropriate.
DE:G0FB Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | 0.30- | 0.15 | ― | ― |
| Nov 02, 2026 | 2026 (Q3) | 0.290.25 | 0.2 | 25.69% (+0.05) | |
| Jul 28, 2026 | 2026 (Q2) | 0.240.24 | 0.17 | 34.87% (+0.06) | |
| May 07, 2026 | 2026 (Q1) | 0.140.11 | 0.08 | 36.96% (+0.03) | |
| Feb 26, 2026 | 2025 (Q4) | 0.270.15 | 0.1 | 55.56% (+0.05) | |
| Nov 04, 2025 | 2025 (Q3) | 0.220.20 | 0.08 | 159.52% (+0.12) | |
| Jul 29, 2025 | 2025 (Q2) | 0.200.17 | 0.02 | 712.50% (+0.15) | |
| May 12, 2025 | 2025 (Q1) | 0.130.08 | 0.03 | 170.59% (+0.05) | |
| Feb 26, 2025 | 2024 (Q4) | 0.210.10 | 0.08 | 21.35% (+0.02) | |
| Nov 07, 2024 | 2024 (Q3) | 0.190.08 | 0.13 | -44.00% (-0.06) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


